XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 12,624us-gaap_CashAndCashEquivalentsAtCarryingValue $ 10,923us-gaap_CashAndCashEquivalentsAtCarryingValue
Marketable securities 17,597us-gaap_AvailableForSaleSecuritiesCurrent 29,790us-gaap_AvailableForSaleSecuritiesCurrent
Prepaid expenses and other current assets 950us-gaap_PrepaidExpenseAndOtherAssetsCurrent 1,532us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 31,171us-gaap_AssetsCurrent 42,245us-gaap_AssetsCurrent
Property and equipment, net 473us-gaap_PropertyPlantAndEquipmentNet 414us-gaap_PropertyPlantAndEquipmentNet
Restricted cash 193us-gaap_RestrictedCashAndCashEquivalentsNoncurrent 193us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
Other assets 113us-gaap_OtherAssets 125us-gaap_OtherAssets
Total assets 31,950us-gaap_Assets 42,977us-gaap_Assets
Current liabilities:    
Accounts payable 857us-gaap_AccountsPayableCurrent 1,822us-gaap_AccountsPayableCurrent
Accrued compensation 1,267us-gaap_EmployeeRelatedLiabilitiesCurrent 1,400us-gaap_EmployeeRelatedLiabilitiesCurrent
Deferred rent, short-term 21us-gaap_DeferredRentCreditCurrent 16us-gaap_DeferredRentCreditCurrent
Accrued research and clinical liabilities 3,311kbio_AccruedResearchAndClinicalLiabilities 3,470kbio_AccruedResearchAndClinicalLiabilities
Notes payable, short-term 9,677us-gaap_NotesPayableCurrent 10,928us-gaap_NotesPayableCurrent
Financing derivative 92us-gaap_FinancialLiabilitiesFairValueDisclosure 89us-gaap_FinancialLiabilitiesFairValueDisclosure
Other accrued liabilities 315us-gaap_OtherAccruedLiabilitiesCurrent 328us-gaap_OtherAccruedLiabilitiesCurrent
Total current liabilities 15,540us-gaap_LiabilitiesCurrent 18,053us-gaap_LiabilitiesCurrent
Deferred rent, long-term 305us-gaap_DeferredRentCreditNoncurrent 311us-gaap_DeferredRentCreditNoncurrent
Total liabilities 15,845us-gaap_Liabilities 18,364us-gaap_Liabilities
Commitments and contingencies      
Stockholders' equity:    
Common stock, $0.001 par value: 85,000,000 shares and 85,000,000 shares authorized at March 31, 2015 and December 31, 2014 respectively; 32,992,178 and 32,992,178 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively 33us-gaap_CommonStockValue 33us-gaap_CommonStockValue
Additional paid-in capital 203,909us-gaap_AdditionalPaidInCapital 202,801us-gaap_AdditionalPaidInCapital
Accumulated other comprehensive income (2)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (8)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Accumulated deficit (187,835)us-gaap_RetainedEarningsAccumulatedDeficit (178,213)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders’ equity 16,105us-gaap_StockholdersEquity 24,613us-gaap_StockholdersEquity
Total liabilities and stockholders’ equity $ 31,950us-gaap_LiabilitiesAndStockholdersEquity $ 42,977us-gaap_LiabilitiesAndStockholdersEquity